Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2006 Nov 1;16(21):5555-60. Epub 2006 Aug 23.

Discovery of orally active butyrolactam 11beta-HSD1 inhibitors.

Author information

1
Metabolic Disease Research, Abbott Laboratories, 100 Abbott Park Road, AP-10-304B, Abbott Park, IL 60064, USA. vince.yeh@abbott.com

Abstract

A series of metabolically stable butyrolactam 11beta-HSD1 inhibitors have been synthesized and biologically evaluated. These compounds exhibit excellent HSD1 potency and HSD2 selectivity, pharmacokinetic, and pharmacodynamic profiles.

PMID:
16931002
DOI:
10.1016/j.bmcl.2006.08.034
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center